ClinicalTrials.gg
Drug

DC-806 clinical trials

Also written DC-806 and LY4100504.

studies test it
5
open now
0
in phase 3
0
first study started
2021

How each study uses DC-806 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

DC-806
5
LY4100504
2

Studies by the year they started

5 studies that test it; most in 2023 (4)

Studies that test DC-806, by start year
YearStudies
20211
20234

By phase

A phase 1/2 study counts in both.

Phase 1
4
Phase 2
1

Who runs them

Industry 5 · Other 0

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company (5)

Studies

Open first, then newest update. How each study uses DC-806 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 5